BioCentury
ARTICLE | Clinical News

Hsp90 inhibitor: Preliminary Phase II data

June 11, 2012 7:00 AM UTC

Preliminary data from an open-label, international Phase II trial in 112 patients with advanced NSCLC who failed >=2 prior lines of chemotherapy showed that 70 mg/m 2 IV AUY922 produced 13 partial responses. The most common adverse events reported were diarrhea, visual and nausea. The trial enrolled patients with EGFR-activating, K-Ras or anaplastic lymphoma kinase (ALK)-positive mutations or wild-type NSCLC. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...